The Patent Finder
US

Sublingual Apomorphine

US 9,044,475 In force, term unresolved
OverviewFamilyAssignmentsSources & methods

Term ends no later than Jun 11, 2030 · Medium confidence

In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.

Filed Jun 11, 2010 as application 12/813,820 · Granted Jun 2, 2015
Base term, 20 years from filing
Today
20 years from filing
2010 2030
Clock starts
Jun 11, 2010
Ends no later than
Jun 11, 2030
Granted
Jun 2, 2015
base term fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 11, 2010, when this application, 12/813,820, was filedJun 11, 2030High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer on file (approved), reference document not resolvedno cap applied, and none guessedMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderno later than Jun 11, 2030Medium confidence

This family

US 9,044,475this patent
no later than Jun 2030
no later than Jun 2030
US 9,326,981In force
Jun 2030
Jun 2030
Application 14/962,806Abandoned
not computed
not computed
US 9,669,018Lapsed on the fee record
Jun 2025
Jun 2025
US 9,669,020Lapsed on the fee record
Jun 2025
Jun 2025
US 9,669,019Lapsed on the fee record
Jun 2025
Jun 2025
US 9,669,021Lapsed on the fee record
Jun 2025
Jun 2025
US 10,420,763In force
no later than Jun 2030
no later than Jun 2030
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jan 21, 2011
Reel 25677, frame 57
Bryson, Nathan JohnCynapsus Therapeutics, Inc.Assignment of Assignor's Interest
Jan 21, 2011
Reel 25677, frame 236
Giovinazzo, Anthony John; Hedden, David Bruce; De Somer, MarcAdagio Pharmaceuticals, Ltd.Assignment of Assignor's Interest
Feb 23, 2015
Reel 35007, frame 774
Adagio Pharmaceuticals, Ltd.Cynapsus Therapeutics, Inc.Assignment of Assignor's Interest
Nov 10, 2016
Reel 40277, frame 773
Sunovion CNS Development Canada ULCSunovion Pharmaceuticals Inc.Assignment of Assignor's Interest
Nov 10, 2016
Reel 40587, frame 262
Cynapsus Therapeutics Inc.Project Pegasus Sub Acquisition ULCAssignment of Assignor's Interest
Nov 10, 2016
Reel 40588, frame 155
Project Pegasus Sub Acquisition ULCSunovion CNS Development Canada ULCMerger
Dec 15, 2016
Reel 40940, frame 603
Sunovion CNS Development Canada ULCSunovion Pharmaceuticals Inc.Corrective Assignment to Correct the Effective Date of Assignment Previously Recorded at Reel: 040277 Frame: 0773. Assignor(S) Hereby Confirms the Assignment.

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited